title: Atorvastatin and pravastatin elevated pre-heparin lipoprotein lipase mass of type 2 diabetes with hypercholesterolemia.
abstract: To clarify whether 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statin) increases lipoprotein lipase mass in preheparin plasma (preheparin LPL mass), we observed the change in preheparin LPL mass during administration of atorvastatin and pravastatin to type 2 diabetes mellitus patients with hypercholesterolemia. The subjects were randomly divided into two groups. One group was 24 patients given atorvastatin (10 mg/day), and the other was 23 patients given pravastatin (20 mg/day) for 4 months. After 4 months of administration, no significant change of HbA1c was observed. TC significantly decreased in the atorvastatin group compared to the pravastatin group. TG significantly decreased in the atorvastatin group. Low density lipoprotein cholesterol level significantly decreased in both groups (- 36.3%, p < 0.01 in atorvastatin, - 24.3%, p < 0.01 in pravastatin). Preheparin LPL mass slightly increased in both groups after 4 months of administration. Especially in patients who showed low preheparin LPL mass (less than 50 ng/ml) before statin administration, preheparin LPL mass significantly increased in both groups (+ 25.8% in the atorvastatin group, + 24.39% in the pravastatin group). These results suggested that administration of atorvastatin and pravastatin to type 2 diabetic patients with hypercholesterolemia increased serum preheparin LPL mass concentration. Especially, its effect was remarkable in patients who showed low preheparin LPL mass.
authors.affiliation: The Center of Diabetes, Endocrine and Metabolism, Sakura Hospital, Toho University School of Medicine, 564-1 Shimoshizu, Sakura, Chiba 285-0841, Japan.
authors.forename: Kei
authors.initials: K
authors.lastname: Endo
authors.forename: Yoh
authors.initials: Y
authors.lastname: Miyashita
authors.forename: Atsuhito
authors.initials: A
authors.lastname: Saiki
authors.forename: Tomokazu
authors.initials: T
authors.lastname: Oyama
authors.forename: Nobukiyo
authors.initials: N
authors.lastname: Koide
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Ozaki
authors.forename: Masaki
authors.initials: M
authors.lastname: Otsuka
authors.forename: Yoshiaki
authors.initials: Y
authors.lastname: Ito
authors.forename: Kohji
authors.initials: K
authors.lastname: Shirai
mesh_terms: D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D000069059:Atorvastatin; D003924:Diabetes Mellitus, Type 2 / Q000150:complications* / Q000201:enzymology; D006538:Heptanoic Acids / Q000627:therapeutic use*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D006937:Hypercholesterolemia / Q000150:complications / Q000188:drug therapy* / Q000201:enzymology; D008071:Lipoprotein Lipase / Q000378:metabolism*; D008875:Middle Aged; D017035:Pravastatin / Q000627:therapeutic use*; D011758:Pyrroles / Q000627:therapeutic use*
chemical_list: D000924:Anticholesteremic Agents; D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011758:Pyrroles; D000069059:Atorvastatin; D008071:Lipoprotein Lipase; D017035:Pravastatin